3P Biopharmaceuticals enters into a new manufacturing agreement with the Dutch Biotech Company Xenikos

by 3P Biopharmaceuticals

5 years ago
3P Biopharmaceuticals, contract, collaboration, Xenikos, T-Guard, transplant

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Dutch biotech company Xenikos B. V. (Xeni...

3P Biopharmaceuticals successfully completes the expansion and improvement of its facilities

by 3P Biopharmaceuticals

5 years ago
facilities, 3P Biopharmaceuticals, bioprocesses, manufacturing plant, Robustness

3P Biopharmaceuticals has successfully completed the project for the expansion and improvement of its facilities in Noáin (Spain) that had been carried out over the past months. The investment exceed...

3P Biopharmaceuticals and Viscofan to collaborate in an innovate advanced therapy project

by 3P Biopharmaceuticals

6 years ago
Cardiomesh, cell therapy product, GMP manufacturing

Cardiomesh is the project in which 3P Biopharmaceuticals and Viscofan are collaborating to develop and manufacture an innovative cell therapy product. 3P Biopharmaceuticals has executed the tuning, th...

3P Biopharmaceuticals incorporates a LIMS, a Laboratory Information Management Systems

by 3P Biopharmaceuticals

6 years ago
LIMS, 3P Biopharmaceuticals

This acquisition has involved an investment of approximately 200.000 € (system, implementation and associated services) and it is part of an investment plan that 3P is conducting during 2018 with th...

3P Biopharmaceuticals is proud to announce a new collaboration agreement signed with the Swedish company Intervacc

by 3P Biopharmaceuticals

7 years ago
Intervacc, vaccine, 3P Biopharmaceuticals

Intervacc has signed a Letter of Intent and an agreement on first mile stones with 3P Biopharmaceuticals in Pamplona, Spain, for contract manufacturing of Strangvac®, Intervacc´s recombinant vaccine...

3P Biopharmaceuticals reunió a más de 150 invitados en su décimo aniversario

by 3P Biopharmaceuticals

7 years ago
3P Biopharmaceuticals

3P Biopharmaceuticals es una compañía biotecnológica CDMO (Contract Development Manufacturing Organization) especializada en el desarrollo de procesos y fabricación GMP de medicamentos biológicos...

How to select the perfect partner, next CPhI 2015 by 3PBiopharmaceuticals, Charles River, Covance and Menarini Biotech

by 3P Biopharmaceuticals

9 years ago
round table, CPhI, Covance, Charles River, Menarini Biotech, ASEBIO, 3P Biopharmaceuticals

"The challenge of Partner selection: the best travel companion in biologics drug development adventure” will discover the keys to success in this major challenge

3P Biopharmaceuticals Advanced Therapy area develops a GMP buffer involved in a novel treatment for the Age-Related Macular Degeneration (AMD)

by 3P Biopharmaceuticals

9 years ago
TargetAMD, neovascularisation, Age-related Macular Degeneration

The project has received funding from the European Union’s Seventh Framework Programme and aims to develop a non-viral gene therapeutic approach for the treatment of this neurodegenerative disease o...

Infarco, the parent company of Cinfa, makes the leap to biotechnology

by 3P Biopharmaceuticals

10 years ago

The total investment of Infarco in the companies of the group, which currently employ 1,100 people, will be more than 200 million Euros over the next five years.

3P Biopharmaceuticals keeps focused in international markets

by 3P Biopharmaceuticals

10 years ago
3P Biopharmaceuticals

With more than 60% of its portfoloio composed of international clients, 3P has active presence in major international markets such as USA, Australia, Mexico, Argentina, France, Norway, Italy, UK, Belg...

The cell therapy area at 3P Biopharmaceuticals receives GMP certification of an allogeneic cell therapy medicine

by 3P Biopharmaceuticals

10 years ago
stem cells, CRO - CMO Services

This past April, 3P Biopharmaceuticals obtained GMP (Good Manufacturing Practices) certification for a manufacturing process of a cellular medication destined for allogeneic therapy treatments

Interview with Dámaso Molero, general manager in 3P

by 3P Biopharmaceuticals

11 years ago
proteínas

Dámaso Molero: “There are great opportunities in Latin America for the development of biosimilars“ Trescientas compañías han participado en el primer foro Biolatam, del sector biotecnoló...